Stockreport

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs [Yahoo! Finance]

Cocrystal Pharma, Inc.  (COCP) 
NASDAQ:AMEX Investor Relations: cocrystalpharma.com
PDF Expects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026 Granted NIH SBIR award to advance influenza A/B replication inhibitor program BOTHELL, Was [Read more]